1. Residual Risk After Statin Therapy:

3. Residual CVD Risk Despite OMT

4. TG Independently Predicts CVD: Confusion About Adjusting for Non-HDL-C

5. Lipoprotein Lipase Clears Triglycerides From the Circulation

6. Recent Genetic Studies Do Support Causality of TGRLP in CV risk

7. Lipoprotein Lipase: A Central Hub in Metabolism of TGRLP

8. Overview of TG Metabolism

9. Elevated TG Concentrations in Non-Statin-Treated Patients Associated With MACE and MI

10. Increasing TG Levels Increase Risk of Pancreatitis

11. Assessing TGRLP Levels: Which Method Is Best?

12. No Fasting Required: Practical Algorithm for Screening and Managing Elevated TG

13. Treatment Approach for TG ≥ 500 mg/dL to Reduce Risk of Pancreatitis

14. Treatment Approach for TG 200 to 500 mg/dL

15. CV Outcomes Trials in Patients With Hypertriglyceridemia

16. Risk Difference vs Placebo of HTG Subgroups Primary and Secondary CVD Prevention Trials

17. Why Have CVOTs of TG-Lowering Drugs Failed to Reach Primary Endpoints?

18. Fish Oil Supplements vs Prescription Omega-3 FAs

19. What Is on the Horizon?

20. Conclusion